vs
ETHAN ALLEN INTERIORS INC（ETD）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是ETHAN ALLEN INTERIORS INC的1.5倍（$200.5M vs $135.8M），ETHAN ALLEN INTERIORS INC净利率更高（4.4% vs 2.2%，领先2.1%），ROGERS CORP同比增速更快（5.2% vs -4.8%），过去两年ROGERS CORP的营收复合增速更高（-3.3% vs -10.2%）
伊森艾伦内饰公司是美国家居家具制造商与零售商，公司注册于特拉华州，总部行政办公室位于康涅狄格州丹伯里。截至2023年6月30日，该公司年度净销售额达7.914亿美元。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
ETD vs ROG — 直观对比
营收规模更大
ROG
是对方的1.5倍
$135.8M
营收增速更快
ROG
高出10.1%
-4.8%
净利率更高
ETD
高出2.1%
2.2%
两年增速更快
ROG
近两年复合增速
-10.2%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $135.8M | $200.5M |
| 净利润 | $5.9M | $4.5M |
| 毛利率 | 59.4% | 32.2% |
| 营业利润率 | 4.8% | — |
| 净利率 | 4.4% | 2.2% |
| 营收同比 | -4.8% | 5.2% |
| 净利润同比 | -38.2% | 421.4% |
| 每股收益（稀释后） | $0.23 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ETDROG
| Q1 26 | $135.8M | $200.5M | ||
| Q4 25 | $149.9M | $201.5M | ||
| Q3 25 | $147.0M | $216.0M | ||
| Q2 25 | $160.4M | $202.8M | ||
| Q1 25 | $142.7M | $190.5M | ||
| Q4 24 | $157.3M | $192.2M | ||
| Q3 24 | $154.3M | $210.3M | ||
| Q2 24 | $168.6M | $214.2M |
净利润ETDROG
| Q1 26 | $5.9M | $4.5M | ||
| Q4 25 | $11.7M | $4.6M | ||
| Q3 25 | $10.5M | $8.6M | ||
| Q2 25 | — | $-73.6M | ||
| Q1 25 | $9.6M | $-1.4M | ||
| Q4 24 | $15.0M | $-500.0K | ||
| Q3 24 | $14.7M | $10.7M | ||
| Q2 24 | $18.5M | $8.1M |
毛利率ETDROG
| Q1 26 | 59.4% | 32.2% | ||
| Q4 25 | 60.9% | 31.5% | ||
| Q3 25 | 61.4% | 33.5% | ||
| Q2 25 | 59.9% | 31.6% | ||
| Q1 25 | 61.2% | 29.9% | ||
| Q4 24 | 60.3% | 32.1% | ||
| Q3 24 | 60.8% | 35.2% | ||
| Q2 24 | 60.8% | 34.1% |
营业利润率ETDROG
| Q1 26 | 4.8% | — | ||
| Q4 25 | 9.5% | 3.5% | ||
| Q3 25 | 6.8% | 7.3% | ||
| Q2 25 | 9.5% | -33.3% | ||
| Q1 25 | 7.7% | -0.2% | ||
| Q4 24 | 11.5% | -6.6% | ||
| Q3 24 | 11.4% | 6.9% | ||
| Q2 24 | 13.4% | 5.3% |
净利率ETDROG
| Q1 26 | 4.4% | 2.2% | ||
| Q4 25 | 7.8% | 2.3% | ||
| Q3 25 | 7.1% | 4.0% | ||
| Q2 25 | — | -36.3% | ||
| Q1 25 | 6.7% | -0.7% | ||
| Q4 24 | 9.5% | -0.3% | ||
| Q3 24 | 9.5% | 5.1% | ||
| Q2 24 | 11.0% | 3.8% |
每股收益（稀释后）ETDROG
| Q1 26 | $0.23 | $0.25 | ||
| Q4 25 | $0.46 | $0.20 | ||
| Q3 25 | $0.41 | $0.48 | ||
| Q2 25 | $0.48 | $-4.00 | ||
| Q1 25 | $0.37 | $-0.08 | ||
| Q4 24 | $0.59 | $-0.04 | ||
| Q3 24 | $0.57 | $0.58 | ||
| Q2 24 | $0.73 | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.6M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $473.7M | $1.2B |
| 总资产 | $723.3M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ETDROG
| Q1 26 | $66.6M | $195.8M | ||
| Q4 25 | $139.3M | $197.0M | ||
| Q3 25 | $123.6M | $167.8M | ||
| Q2 25 | $136.1M | $157.2M | ||
| Q1 25 | $172.9M | $175.6M | ||
| Q4 24 | $139.1M | $159.8M | ||
| Q3 24 | $135.9M | $146.4M | ||
| Q2 24 | $161.0M | $119.9M |
股东权益ETDROG
| Q1 26 | $473.7M | $1.2B | ||
| Q4 25 | $478.2M | $1.2B | ||
| Q3 25 | $475.5M | $1.2B | ||
| Q2 25 | $482.4M | $1.2B | ||
| Q1 25 | $479.2M | $1.3B | ||
| Q4 24 | $478.8M | $1.3B | ||
| Q3 24 | $474.7M | $1.3B | ||
| Q2 24 | $483.0M | $1.3B |
总资产ETDROG
| Q1 26 | $723.3M | $1.4B | ||
| Q4 25 | $714.8M | $1.4B | ||
| Q3 25 | $737.1M | $1.4B | ||
| Q2 25 | $737.1M | $1.5B | ||
| Q1 25 | $738.7M | $1.5B | ||
| Q4 24 | $732.6M | $1.5B | ||
| Q3 24 | $737.7M | $1.5B | ||
| Q2 24 | $744.9M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $1.1M |
| 自由现金流率自由现金流/营收 | — | 0.5% |
| 资本支出强度资本支出/营收 | — | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | — | $70.1M |
8季度趋势，按日历期对齐
经营现金流ETDROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-1.8M | $46.9M | ||
| Q3 25 | $16.8M | $28.9M | ||
| Q2 25 | $24.8M | $13.7M | ||
| Q1 25 | $10.2M | $11.7M | ||
| Q4 24 | $11.6M | $33.7M | ||
| Q3 24 | $15.1M | $42.4M | ||
| Q2 24 | $26.2M | $22.9M |
自由现金流ETDROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-4.7M | $42.2M | ||
| Q3 25 | $14.4M | $21.2M | ||
| Q2 25 | $22.9M | $5.6M | ||
| Q1 25 | $8.2M | $2.1M | ||
| Q4 24 | $7.8M | $18.3M | ||
| Q3 24 | $11.5M | $25.2M | ||
| Q2 24 | $24.2M | $8.8M |
自由现金流率ETDROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | -3.2% | 20.9% | ||
| Q3 25 | 9.8% | 9.8% | ||
| Q2 25 | 14.3% | 2.8% | ||
| Q1 25 | 5.7% | 1.1% | ||
| Q4 24 | 5.0% | 9.5% | ||
| Q3 24 | 7.4% | 12.0% | ||
| Q2 24 | 14.3% | 4.1% |
资本支出强度ETDROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.6% | 3.6% | ||
| Q2 25 | 1.2% | 4.0% | ||
| Q1 25 | 1.4% | 5.0% | ||
| Q4 24 | 2.4% | 8.0% | ||
| Q3 24 | 2.3% | 8.2% | ||
| Q2 24 | 1.2% | 6.6% |
现金转化率ETDROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | -0.16× | 10.20× | ||
| Q3 25 | 1.61× | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 1.02× | 3.96× | ||
| Q2 24 | 1.42× | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
